Source comparison
Efficacy, Dosing, and IGF-1 Elevation Comparison
Clinical data from a 2008 study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that 25mg daily MK-677 increased mean serum IGF-1 concentrations from 153 ng/mL at baseline to 265 ng/mL after eight weeks. A 73% increase sustained th
This comparison does not assign a generated winner or score.
- Clinical data from a 2008 study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that 25mg daily MK-677 increased mean serum IGF-1 concentrations from 153 ng/mL at baseline to 265 ng/mL after eight weeks. A 73% increase sustained throughout the 12-month trial period. Importantly, IGF-1 levels remained elevated without dose escalation, suggesting no tolerance development. Comparable IGF-1 elevation with recombinant HGH typically requires 2–4 IU daily, though individual response varies based on endogenous production capacity and hepatic IGF-1 conversion efficiency.
- Mean IGF-1 increase
- +73% from baseline
- +60–80% from baseline
- +120–150% from baseline
- MK-677 achieves mid-range physiological elevation; HGH dose-response is steeper but requires titration
- Peak serum GH elevation
- +89% (pulsatile)
- +300–500% (sustained 12–16 hrs)
- +600–800% (sustained)
- HGH produces supraphysiological peaks; MK-677 stays within upper physiological range
- Administration route
- Oral capsule/liquid
- Subcutaneous injection
- MK-677 eliminates injection site reactions, needle phobia, and cold chain storage requirements
- Dosing frequency
- Once daily
- Once daily (sometimes split)
- Once or twice daily
- Equivalent convenience for single daily dose; HGH split dosing improves pulsatility mimicry
- Cost per month (research grade)
- $60–$120
- $400–$800
- $800–$1,600
- MK-677 is 85–95% less expensive at equivalent IGF-1 outcomes
- HPTA suppression risk
- None (works via ghrelin pathway)
- Complete suppression within 2 weeks
- MK-677 preserves endogenous production; HGH requires PCT and recovery period post-cessation
- The dose-response curve differs significantly. MK-677 demonstrates a ceiling effect around 25mg daily. Higher doses don't produce proportionally greater IGF-1 elevation but do increase appetite and water retention side effects. Recombinant HGH shows linear dose-response up to 8–10 IU daily before diminishing returns and sharply increased adverse event rates. For research applications targeting muscle protein synthesis and body recomposition, 25mg MK-677 delivers IGF-1 elevation comparable to 2–3 IU daily HGH.
- MK-677's oral bioavailability eliminates injection site complications that occur in 15–25% of long-term HGH users. Oral administration also removes cold chain logistics. MK-677 remains stable at room temperature for 24+ months, while lyophilized HGH requires −20°C storage before reconstitution and 2–8°C refrigeration after mixing.